Research ArticleArticle
Open Access
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi and William Macias
The Journal of Rheumatology January 2019, jrheum.171469; DOI: https://doi.org/10.3899/jrheum.171469
Charles Peterfy
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Julie DiCarlo
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Paul Emery
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Mark C. Genovese
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Edward C. Keystone
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Peter C. Taylor
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Doug E. Schlichting
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Scott D. Beattie
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
Monica Luchi
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
William Macias
From Spire Sciences Inc., Boca Raton, Florida; Division of Immunology and Rheumatology, Stanford University, Stanford, California; Eli Lilly and Co., Indianapolis, Indiana; Incyte Corporation, Wilmington, Delaware, USA; The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds; Botnar Research Centre, University of Oxford, Oxford, UK; Department of Rheumatology, University of Toronto, Toronto, Ontario, Canada. This study was funded by Eli Lilly and Co. and Incyte Corp., which jointly developed baricitinib. Dr. DiCarlo was an employee of Spires Science Inc. at the time of this study. Dr. Luchi was an employee of Incyte Corp. at the time of this study. Dr. Macias was an employee of Eli Lilly and Co. at the time of this study. C. Peterfy, MD, PhD, Spire Sciences Inc.; J. DiCarlo, PhD, Spire Sciences Inc.; P. Emery, MD, FRCP, The Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; M.C. Genovese, MD, Division of Immunology and Rheumatology, Stanford University; E.C. Keystone, MD, FRCP, Department of Rheumatology, University of Toronto; P.C. Taylor, MA, PhD, FRCP, Botnar Research Centre, University of Oxford; D.E. Schlichting, RN, PhD, Eli Lilly and Co.; S.D. Beattie, PhD, Eli Lilly and Co.; M. Luchi, MD, FACR, MBA, Incyte Corp.; W. Macias, MD, PhD, Eli Lilly and Co. Address correspondence to Dr. C. Peterfy, Spire Sciences Inc., 5314 Boca Marina Circle N, Boca Raton, Florida 33487, USA. E-mail: charles.peterfy@spiresciences.com. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication January 4, 2019.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi, William Macias
The Journal of Rheumatology Jan 2019, jrheum.171469; DOI: 10.3899/jrheum.171469
MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
Charles Peterfy, Julie DiCarlo, Paul Emery, Mark C. Genovese, Edward C. Keystone, Peter C. Taylor, Doug E. Schlichting, Scott D. Beattie, Monica Luchi, William Macias
The Journal of Rheumatology Jan 2019, jrheum.171469; DOI: 10.3899/jrheum.171469